Inhalation and oral toxicity studies of ethyl parathion administered acutely and subacutely to the rat and dog
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

For very narrow results

When looking for a specific result

Best used for discovery & interchangable words

Recommended to be used in conjunction with other fields

Dates
...

to

...
Document Data
Library
People
Clear All
...
Clear All

For additional assistance using the Custom Query please check out our Help Page

CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners. As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
i

Inhalation and oral toxicity studies of ethyl parathion administered acutely and subacutely to the rat and dog



English

Details:

  • Alternative Title:
    Parathion -- inhalation and oral toxicity studies on rats and dogs
  • Corporate Authors:
  • Description:
    Handwritten on title page: “Parathion -- inhalation and oral toxicity studies on rats and dogs performed for NIOSH by Toxicology Division, Edgewood Arsenal, Aberdeen Proving Ground, Maryland, 89 pages.”

    Acute and subacute oral and inhalation toxicity of ethyl parathion (56382) was studied in male Sprague-Dawley-rats crossed with Wistar-rats and male Beagle-dogs. Experimental animals received single acute or subacute doses administered over 6 weeks. Median lethal concentration (LC50) for rats in acute inhalation studies was 84.00 milligrams per cubic meter (mg/m3). The red blood cell (RBC) median cholinesterase activity inhibition concentration was 5.43mg/m3, and the plasma median cholinesterase activity inhibition concentration was 7.28mg/m3. Toxic signs included tremors, convulsions, salivation, respiratory difficulty, and death. Dogs were acutely exposed to concentrations ranging from 0.0153 to 37.13mg/m3. Cholinesterase activity was inhibited at all exposure concentrations. In acute oral studies, the LD50 for rats was 6.85mg/kilogram (kg), the RBC median cholinesterase activity inhibition concentration was 2.58mg/kg, and the plasma median cholinesterase activity inhibition concentration was 2.5mg/kg. Tremors, salivation, convulsions, prostration, and death were observed. In dogs, the acute oral LD50 was 8.27mg/kg, the RBC median cholinesterase activity inhibition concentration was 1.5mg/kg, and the plasma median cholinesterase inhibition activity concentration was 1.67mg/kg. Tremors, convulsions, and death were observed. In subacute inhalation studies, 0.01mg/m3 had no effects in rats, whereas doses of 0.10 and 0.74mg/m3 had moderate and pronounced effects, respectively. In dogs, 0.001mg/m3 subacute inhalation exposure had no effects, whereas 0.01 and 0.20mg/m3 had moderate and pronounced effects, respectively. In subacute oral toxicity tests the ethyl parathion concentrations producing no effect, moderate effects, and pronounced effects on RBC and plasma cholinesterase activity in rats were 0.05, 0.10, and 0.25mg/kg, respectively. The corresponding values in dogs were 0.05, 0.10, The authors suggest that human exposure levels can be predicted from observed effects on RBC or plasma cholinesterase activity.

    NIOSHTIC No. 00134578

  • Subjects:
  • Document Type:
  • CIO:
  • Pages in Document:
    98 numbered and unnumbered pages
  • NIOSHTIC Number:
    00134578
  • Collection(s):
  • Main Document Checksum:
  • Download URL:
  • File Type:
    Filetype[PDF-4.10 MB]

You May Also Like

Checkout today's featured content at stacks.cdc.gov